Corporate Presentation

Corporate Presentation
Who we are
 A fully integrated pharmaceutical group in Greece
with a 100-year history
 We develop, manufacture, import, market, distribute
and export pharmaceutical, OTC and dermocosmetic
products
 Partner of choice for major international
pharmaceutical and consumer health companies in
Greece and abroad
 Growing player in pharmaceutical technologies
focusing on novel drug delivery and solubilisation
areas
 Focus on international expansion
 Well positioned for short, medium and long term
growth
Historical Highlights
1911 Establishment of Lavipharm
1914 Launch of Digitaline, an innovative cardiovascular product, in
Greece
1958 Launch of Nitroglycerin Controlled Release tablets
1976 Dr. A. Lavidas with new management team
1977 Collaboration with L’Oreal - first to sell cosmetics through
pharmacies in Greece
1979 Construction of plant for the production of drugs & cosmetics
1985 Establishment of R&D department focused on drug delivery
technologies
1989 Establishment of Laboratoires Lavipharm in Paris
1992 Joint Ventures with Synthelabo-France (Synthelabo Lavipharm)
and L’Oreal Cosmetique Active (Lavicosmetica)
1992 Completion of transdermal production unit in Greece
1993 Establishment of LAS, the Group’s wholesaling and distribution
center
1995 Listing of Lavipharm S.A. on the Athens Stock Exchange
Launch of nitroglycerin transdermal patch in Italy and France
Historical Highlights
1996 Acquisition of U.S. based R&D unit specialised in TDDS (now
Lavipharm Laboratories Inc)
1997 Launch of patented acne epidermal patch worldwide by L’Oreal
2000 Acquisition of 30% of Phasex (U.S.A.) specialized in SCF
2006 FDA approval of Lavipharm's fentanyl transdermal system in the
USA
2007 Fentanyl patch launch in Greece
2008 Fentanyl patch launch in Germany
Co-marketing with Pfizer Hellas for Lavipharm’s nitroglycerin
transdermal system Trinipatch® in the Greek market
2010 DCP Regulatory Approval for Lavipharm’s fentanyl patch in 20
countries
Fentanyl patch approval in France (national)
Co-marketing with Pfizer Hellas for Lavipharm’s fentanyl
transdermal system Dolfen® in Greece
2011 Establishment of Lavipharm Srl in Italy
2012 Strategic collaboration with the Belgian company Tilman,
Phytotherapy Specialists
2013 Pharma PLUS’ opens up to pharmacists as new shareholders
through Capital Increase
Operation Centers
Greece



France
Headquarters
Production / Distribution
Commercial activity
Pharma (Rx & OTC), Dermocosmetics

Paris: Rx/Dermocosmetics
Food Supplements
U.S.A.


NJ: Commercial Activity
Pharma US & Canada
R&D Pharma/ OTC
Lavipharm S.A.
Headquarters: Peania, Attica
Turnover 2012 : € ~38 million
Listed on the Athens Exchange
since 1995 (ASE : ΛΑΒΙ)
Core Activities
I.
Research & Development
II. Manufacturing
III. Pharmaceuticals
IV.
Consumer Health / OTC
V.
Dermocosmetics
VI.
Wholesaling - Logistics
VII. Pharmacy Services
I.
Research & Development
Greece
Headquarters, Lavipharm SA
 Natural Products
 Commercial / Industrial Production
USA
New Jersey- Lavipharm Laboratories
 Drug Delivery Technologies
 Clinical Manufacturing
I.
Research & Development
Drug
Discovery
Pharma
Pre-Formulation
Development
Dosage Formulation
Development
Lavipharm Field of Activity
Molecule
Design
• Organic
Chemistry
• Biotechnology
• Combinatorial
Chemistry
Formulation/
Particle Design
• Physical
Chemistry
• Physics
• Chemical
Engineering
Drug Delivery
Devices
• Pharmaceutics
• Physical Chemistry
• Chemical
Engineering
• Clinical Science
I. Research & Development
Pharma
 Transdermal (TDDS)
 Intra – oral (IODS)
 Osmotic (OODS)
Protective Backing
Removable
layer
Drug in adhesive matrix
I. Research & Development
Cosmetic Technologies
II. Manufacturing
PHARMACEUTICALS
Tablets
830 million tabs
Capsules
47 million caps
TTDS
140 million pouches
Liquid
23 million bottles
Creams & Ointment
8 million tubes
COSMETICS / OTC
Creams & Emulsions
4.5 million tubes
Shampoos & Lotions
6 million bottles
III. Pharmaceuticals
 Therapeutic Categories:
a)
b)
c)
d)
e)
f)
Cardiology
Chronic Pain & Oncology
CNS
Dermatology
General Medicine & Respiratory
Urology
III. Pharmaceuticals
Lavipharm’ s Pharmaceutical Products
 Chronic Pain &  Cardiology:
 General Medicine, CNS & Respiratory:
Oncology:
 Caprilon®
 Mundisal Gel®
 Nitrong TTS®
 Fentadur®
 Memodrin®
 Terbigram®
 Nitrong® 2,6mg
 Prostaplant ®
 Nitrolingual
 Pricital®
 Lanex ®
 Kerlone®
 Theodur®
 X-Prep®
 Lacitens®
 Pravalip®
III. Pharmaceuticals
Greece
Main cooperations
III. Pharmaceuticals
Global Market
 NITROGLYCERIN TRANSDERMAL
(launched in EU/Canada)
 FENTANYL TRANSDERMAL
(launched in most countries of the EU)
 OTHER TRANSDERMALS
(under development)
 THIN FILM OTC products
(under development)
III. Pharmaceuticals
Global Market
Main Distributors
International presence
IV. Consumer Health / OTC
Main Products:
 BETADINE (antiseptic)
 LAVISEPT (instant antiseptic)
 ALGON (pain reliever)
 IVALITEN, LAVITEN (anti-lice)
 LACTAL (gyn)
 TILMAN (supplements/cough & cold remedies)
IV. Consumer Health/OTC
Greece
Main Cooperations
V. Dermocosmetics
 Brand philosophy “20 year expertise in skin biology”
 Promoted to Dermatologists
 Clinically proven efficacy
 Sold exclusively in pharmacies in 16 countries globally
MORE THAN 20 YEARS OF KNOWLEDGE
IN THE BIOLOGY OF THE SKIN
VI. Wholesaling – Logistics

Logistics services to pharmacies, hospitals and
wholesalers

Fully automated warehouse (600 orders per hour)
VII. Pharmacy Services
We provide our customers (pharmacies) with:
 Fully integrated supply chain center
 Integrated I.T. system
 Agreements with health care products'
suppliers
 Up-to-date product data base with continuous
back up
 Educational / Training programs
 Marketing activities
 Pioneer design layout for common identity
 Category management
 Business plan
 Monthly Reports
 Health & Beauty +pluscard
 Quarterly edition of Pharma Plus Link, a Health
and Wellbeing magazine for the pharmacy
consumer
70
cooperating pharmacies in the largest
cities across country
Visit us @
www.lavipharm.com